Evidence map›Paper›PMID 18238736›Full record

Trial reportEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.

Prakash Chandra, José Nilo G Binongo, Thomas R Ziegler, Lynn E Schlanger, Wenli Wang, James T Someren, Vin Tangpricha

2 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00427037 nacompletednot on this map

Efficacy of Cholecalciferol (Vitamin D3) Therapy in Correcting Vitamin D Insufficiency and Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease: A Randomized, Placebo Controlled Pilot Study

TypeinterventionalSponsorAtlanta VA Medical CenterRan2005 to 2013Enrolled34ConditionsChronic Kidney Disease, Vitamin D DeficiencyArmsCholecalciferol, Placebo
NCT02066441 nacompletednot on this map

The Effect of Vitamin D on Serum Vitamin D Levels, Bone Formation, Resorption, and Mineral Density, Inflammation, Flexibility, and Balance in the Elderly

TypeinterventionalSponsorUniversity of MiamiRan2014 to 2015Enrolled101ConditionsFamily MemberArmsBio-D-Mulsion Forte®, Placebo
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4: results of a 12-week double-blind, randomized, controlled study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2018
    Trial
  5. Efficacy of vitamin DTrials · 2017
    Trial
  6. Trial
  7. Nutritional vitamin D supplementation in dialysis: a randomized trial.Clinical journal of the American Society of Nephrology : CJASN · 2015
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. The role of nutritional vitamin D in chronic kidney disease-mineral and bone disorder in children and adults with chronic kidney disease, on dialysis, and after kidney transplantation-a European consensus statement.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  18. Vitamin D: are all compounds equal?Clinical kidney journal · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Prakash ChandraDepartments of Nutrition and Health Sciences, Emory University, Atlanta, Georgia 30322, USA.
José Nilo G Binongo
Thomas R Ziegler
Lynn E Schlanger
Wenli Wang
James T Someren
Vin Tangpricha

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Role of T-cells in Osteoporosis in Women Undergoing Surgical MenopauseK23AR054334 · NIAMS · EMORY UNIVERSITY · PI TANGPRICHA, VIN · 2007 to 2011
$641k
NCATS NIH HHS UL1 TR000454NIAMS NIH HHS K23 AR054334NIAMS NIH HHS K23AR054334
6 · The paper itself

Abstract

objectiveTo investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD).

methodsIn this double-blind, randomized controlled pilot study, participants with CKD stage 3 and 4 (estimated glomerular filtration rate, 15-59 mL/min/1.73 m2), vitamin D insufficiency (serum 25[OH]D <30 ng/mL), and serum intact PTH levels >70 pg/mL were randomly assigned to receive either 50 000 IU of cholecalciferol or placebo once weekly for 12 weeks. Primary outcomes (25[OH]D and PTH levels) were measured at baseline, week 6, and week 12. Secondary outcomes (1,25-dihydroxvitamin D and bone turnover markers) were measured at baseline and week 12. Because of skewed data distribution, statistical analyses were performed on a logarithmic scale. The difference between the group means was exponentiated to provide the geometric mean ratio. A linear mixed model using an unstructured variance-covariance matrix was used to examine change in the primary and secondary outcomes over time.

resultsGeometric mean serum 25(OH)D concentrations of the study groups were similar at baseline (P = .77). At week 6, a significant difference between the treatment and placebo groups was detected (P = .001); this difference was maintained at week 12 (P = .002). Among cholecalciferol-treated participants, serum 25(OH)D concentration increased on average from 17.3 ng/mL (95% confidence interval [CI], 11.8-25.2) at baseline to 49.4 ng/mL (95% CI, 33.9-72.0) at week 12. As-treated analysis indicated a trend toward lower PTH levels among cholecalciferol-treated participants (P = .07).

conclusionWeekly cholecalciferol supplementation appears to be an effective treatment to correct vitamin D status in patients with CKD.

Indexed as

Acid PhosphataseAdolescentAdultAgedAged, 80 and overAlkaline PhosphataseCalciumCholecalciferolCollagen Type IDouble-Blind MethodHumansIsoenzymesMiddle AgedParathyroid HormonePeptidesPilot ProjectsAcid PhosphataseAlkaline PhosphataseCalciumCholecalciferolCollagen Type Icollagen type I trimeric cross-linked peptideIsoenzymesParathyroid HormonePeptidesPlacebosTartrate-Resistant Acid PhosphataseVitamin D

Identifiers

PMID18238736
PMCPMC2654595

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.